Inhibition of Endothelin-B Receptor Signaling Synergizes with MAPK Pathway Inhibitors in BRAF Mutated Melanoma

The authors demonstrated that the endothelin-endothelin receptor B signaling pathway conferred resistance to MAPK pathway inhibitors in BRAF mutated melanoma.